Phase 2 N=31 A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
Androgenetic Alopecia
Primary: Mean Change From Baseline in Target Area Hair Count (TAHC) — 8.6 hairs/cm^2
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=96 Study of Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy
Tendinopathy
Primary: The Western Ontario Rotator Cuff (WORC) Patient Reported Outcome (PRO) Score at Week 14 in All Patients - Statistical Analysis Results of Total WORC Scores at Week 14…
N/A N=482 DiamondTemp™ Ablation System for the Treatment of Paroxysmal Atrial Fibrillation
Paroxysmal Atrial Fibrillation · Atrial Fibrillation
Primary: Safety: Freedom From a Composite of Pre-specified Serious Adverse Events (SAEs) — 231; 227; 8; 16 Participants — p=<0.0001
N/A N=410 Concussion Device Audiological Measures
Concussion · Traumatic Brain Injury
Primary: Number of Participants Undergoing Acoustic Reflectance — 410; 410 participants — p=<0.05
Phase 4 N=107 A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients
Prostate Cancer
Primary: Number of Participants With Eligard Related Adverse Events (AE) — 15; 2 Participants
Phase 4 N=226 A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.
Prostate Cancer
Primary: Number of Subjects With BR Events — 35; 26 Participants
N/A N=49 Cognitive Dysfunction in Parkinson's Disease
Parkinson's Disease
Primary: Change in Magnetoencephalography (MEG) Connectivity Measures
N/A N=62 Protection Against Potential Brain Injury During Competitive Football
Concussion
Primary: Determine Average Number of Hits Between Groups — 896.43; 795.40; 144.67; 145.85 number of hits
N/A N=380 Diabetes Prevention Program Lifestyle Intervention in the Marshallese Population
Diabetes Mellitus, Type 2
Primary: Change in Mean Body Weight (kg) — 86.44; 84.32; 86.47; 84.40 Kilograms — p=0.3599
Phase 4 N=74 Modified Pre-operative Oral Doses Acetaminophen Versus Intravenous Acetaminophen
Tonsillectomy · Adenoidectomy
Primary: Total Dose of Opioid — 147.6; 125.4 mcg/kg — p=0.127
Phase 4 N=26 SUBLOCADE Rapid Initiation Study
Opioid-use Disorder
Primary: Participants Who Experienced Any Precipitated Withdrawal Within One Hour After SUBLOCADE Administration — 1 Participants
Phase 2 N=6 Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Leukemia · Lymphoma · Multiple Myeloma and Plasma Cell Neoplasm
Primary: Number of Participants With Engraftment Failure — 1 Participants
Phase 3 N=101 Femoral Nerve Block With Liposome Bupivacaine for Postsurgical Analgesia Following Total Knee Arthroplasty
Postoperative Pain
Primary: Area Under the Curve (AUC) of Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores Through 72 Hours — 533.4; 427.2; 436.2; 530.5 score on a scale * hr — p=0.9494
Phase 1 N=53 Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults
HIV-1 Infection
Primary: Part A and Part B: Maximum Reduction From Day 1 (Baseline) Through Day 10 in Plasma HIV-1 RNA — -1.35; -1.79; -1.76; -2.20 log10 copies/mL — p=<0.0001
Phase 2 N=136 Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer
ER+ and AR+ Breast Cancer
Primary: Clinical Benefit Rate, in Centrally Confirmed Androgen Receptor (AR)+ Subjects — 16; 15 participants